Interleukin-2 receptor signaling: at the iterface between tolerance and immunity, Immunity, vol.33, pp.153-65, 2010. ,
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nat Rev Immunol, vol.15, pp.283-94, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01617541
Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes, Diabetes, vol.64, pp.2172-83, 2015. ,
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis, N Engl J Med, vol.365, pp.2067-77, 2011. ,
Low-dose IL-2 induces regulatory T cell-mediated control of experimental food allergy, J Immunol, vol.197, pp.188-98, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01617587
Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med, vol.365, pp.2055-66, 2011. ,
Pharmacokinetics of recombinant interleukin 2 in humans, Cancer Res, vol.50, pp.2009-2026, 1990. ,
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients, J Autoimmun, vol.58, pp.48-58, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01112156
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, vol.1, pp.295-305, 2013. ,
PharmD Clinicians and recruiting centers-Department of Gastroenterology, PhD Biological Investigation: M. Rosenzwajg, MD Modeling and Interim Analysis Clinical Pharmacology ,
Salp^ etri ere Hospital (Prof. B. Fautrel, MD, PhD); Department of Dermatology ,
, MD, PhD) THE DF-IL2 STUDY GROUP Principal Investigator: Prof. D. Klatzmann, MD, PhD Principal Clinical Investigator: Prof A. Hartemann, MD Methodologist: G. Bensimon, MD Data Management & Statistical Analysis: C. A. Payan, MD Clinical Investigations Center-Centre d'Investigation Clinique
PhD Treatment Management Pharmacy, Piti e-Salp^ etri ere Hospital, AP-HP ,
Piti e-Salp^ etri ere Hospital, AP-HP ,
, MD
Dynamics and modeling of Treg cells in mice treated with IL2. Results are expressed as relative variation compared with the PBS-treated group. These data are from a pool of 3 different experiments (n 5 10) using C57BL/6 mice. Treg-cell dynamics in blood at 2 and 24 hours postinjection (A) and Treg-cell dynamics in blood and spleen at 2 hours postinjection (B) ,
Dynamics of Treg cells in blood during a 5-day course of 50,000 IU of IL-2 and then reinjection every 3, 7, or 15 days with 50,000 IU of IL-2. Comparison between IL-2 and PBS groups was done using the Mann-Whitney test ,
,
, , vol.0001